Given the proven benefits in the treatment of heart failure with reduced ejection fraction (HFrEF) over recent decades, particular interest has focused on the potential role of beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-II-receptor blockers (ARBs) and mineralocorticoid receptor antagonists, and more recently angiotensin-receptor-neprilysin inhibitors (ARNIs) and sodium-glucose transporter 2 (SGLT2) inhibitors [21,22]. This evidence concerns the gene SLC5A2 and heart failure.